How Davis was paid
$15.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| James E. DavisChairman, Chief Executive Officer and President | $1,250,000 | $8,762,861 | $2,999,873 | $2,205,844 | $279,901 | $15,498,479 |
| Sam A. SamadExecutive Vice President and Chief Financial Officer | $693,269 | $2,190,967 | $749,742 | $710,358 | $82,805 | $4,427,141 |
| Catherine T. DohertyExecutive Vice President, Regional Businesses | $643,269 | $1,679,674 | $574,876 | $615,184 | $49,943 | $3,562,946 |
| Michael E. PrevoznikSenior Vice President and General Counsel | $550,000 | $1,132,015 | $387,343 | $438,323 | $55,912 | $2,563,593 |
| Karthik KuppusamySenior Vice President, Clinical Solutions | $568,269 | $1,095,483 | $374,893 | $475,526 | $65,652 | $2,579,823 |
What changed and why
- $15.5MCEO total compensation increased to $15,498,479 in 2025 from $14,404,862 in 2024.
- 91%Stockholders expressed strong support with approximately 91% voting in favor of the say-on-pay proposal in 2025.
- Annual incentives and long-term equity awards continue to align executive pay with performance and strategic goals.
- $97,518Perquisites for the CEO included personal use of company aircraft valued at $97,518.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.